Recent Updates
Recently added Catalysts
CGTX Positive Sentiment

Results from COG0201: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild-to-Moderate Alzheimer’s Disease

Monday, July 29, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The study COG0201 evaluated the safety and efficacy of CT1812 in patients with mild-to-moderate Alzheimer's disease. Conducted as a randomized, double-blind, placebo-controlled trial, the results were presented at the 2024 Alzheimer’s Association International Conference in Philadelphia. The findings suggest potential benefits of CT1812 for this patient population.
Price reaction · baseline $2.37 (2024-07-26 close) · hit pre-market · 4 other CGTX headline(s) in the window, move may be shared
day 0 close
-43.9%
day 1
-53.6%
day 3 · peak
-62%

Market Sentiment Analysis

POSITIVE FACTORS

  • CT1812 shows promise in treating mild-to-moderate Alzheimer's disease.
  • The study design is robust, being randomized and double-blind.
  • Results presented at a significant conference highlight the research's relevance.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress

Full Press Release Details

Vijverberg EGB, Catalano S, Hamby ME, et al. Results from COG0201: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild-to-Moderate Alzheimer’s Disease. Poster presented at 2024 Alzheimer’s Association International Conference (AAIC) ; Philadelphia, PA.

Frequently Asked Questions

What was the focus of the COG0201 study?

The COG0201 study focused on evaluating the safety and efficacy of CT1812 in patients with mild-to-moderate Alzheimer's disease.

What type of study design was used in COG0201?

The study was a randomized, double-blind, placebo-controlled trial.

Where were the results of the study presented?

The results were presented at the 2024 Alzheimer’s Association International Conference in Philadelphia.

What is CT1812 being tested for?

CT1812 is being tested for its potential benefits in treating mild-to-moderate Alzheimer's disease.

ShareAdd on Google
Tags: CGTX Viatris Investor Conferences Healthcare CT1812 Alzheimer's disease Phase 2 study COG0201 clinical trial
Last updated: Jul 29, 2024

Biotech snapshot

Cash runway
$34M liquidity · $1M/mo burn
~33 mo
Minimal dilution risk
Lead asset
OxytocinPhase 2
Oxidative Stress →

Catalyst track record

+35%
best trade around CGTX's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for CGTX.

See every catalyst's timing & PoA →